Shire Looks To Europe to Expand ADHD Franchise, But U.S.-Style Success Will Be Tough

Shire Pharmaceuticals PLC built the backbone of its $3 billion business on the U.S. attention deficit hyperactivity disorder (ADHD) market. It now faces an uphill battle as it tries to expand the franchise by tapping into Europe, as part of a broader international push.